Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome - PubMed

Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome - PubMed

Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome

Takashi Mitamura 1 2, Masayuki Sekine 3, Masami Arai 4, Yuka Shibata 2, Momoko Kato 2, Shiro Yokoyama 5, Hiroko Yamashita 6, Hidemichi Watari 1, Ichiro Yabe 2, Hiroyuki Nomura 7, Takayuki Enomoto 3, Seigo Nakamura 5, Registration Committee of the Japanese HBOC Consortium

Affiliations 

• PMID: 32676635
 
• DOI: 10.1093/jjco/hyaa124

Abstract

Background: To establish an individualized surgical strategy for lymphadenectomy in ovarian cancer patients with the germline BRCA1 and BRCA2 pathogenic variants (BRCA1+ and BRCA2+), we investigated the clinicopathological characteristics that are involved in the increased risk of lymph node metastasis.

Methods: We retrospectively reviewed the data of Japanese women registered in the database of the Japanese Hereditary Breast and Ovarian Cancer Consortium, who underwent BRCA1 and BRCA2 genetic testing.

Results: We evaluated the predictors of lymph node metastasis in all patients with the information of age at the diagnosis, disease site, histological subtype, 2014 FIGO stage, personal breast cancer history and family history; 233, 153 and 32 patients in the BRCA- (no pathogenic variant), BRCA1+ and BRCA2+ groups, respectively. The prevalence of lymph node metastasis was not markedly different between BRCA- (20.0%), BRCA1+ (18.4%) and BRCA2+ (26.2%). Multivariate analysis revealed an absence of a family history of ovarian cancer as an independent predictor for an increased risk of lymph node metastasis in BRCA1+, and the prevalence of lymph node metastasis was 11.7 and 42.0% in the groups with and without a family history of ovarian cancer, respectively. This subgroup without a family history of ovarian cancer did not show any correlation with a particular variant of BRCA1, including two common variants of c.188 T > A and c.2800C > T.

Conclusions: This study suggested that certain genetic factors related to the penetrance of hereditary breast and ovarian cancer syndrome altered the frequency of lymph node metastasis in BRCA1+ ovarian cancer, and family history may be useful to personalize the indication of lymphadenectomy.

Keywords: family history; hereditary breast and ovarian cancer syndrome; lymph node metastasis; ovarian cancer; penetrance.

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Similar articles

• BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.

  Petrucelli N, Daly MB, Pal T.1998 Sep 4 [updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.PMID: 20301425 Free Books & Documents. Review.
• Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.

  Piver MS.Oncologist. 1996;1(5):326-330.PMID: 10388011
• Genetic Tests for Breast and Ovarian Cancer [Internet].

  Juvet LK, Natvig Norderhaug I.Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008.PMID: 29319983 Free Books & Documents. Review.
• Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

  Casey MJ, Bewtra C.Fam Cancer. 2004;3(3-4):265-81. doi: 10.1007/s10689-004-9554-y.PMID: 15516851 Review.
• BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.

  Sakamoto I, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, Amemiya K, Mochizuki H, Omata M.Cancer. 2016 Jan 1;122(1):84-90. doi: 10.1002/cncr.29707. Epub 2015 Oct 6.PMID: 26439132